JOP20190022B1 - ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري - Google Patents
ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوريInfo
- Publication number
- JOP20190022B1 JOP20190022B1 JOP/2019/0022A JOP20190022A JOP20190022B1 JO P20190022 B1 JOP20190022 B1 JO P20190022B1 JO P20190022 A JOP20190022 A JO P20190022A JO P20190022 B1 JOP20190022 B1 JO P20190022B1
- Authority
- JO
- Jordan
- Prior art keywords
- disubstituted
- crystalline
- pyrazolyl steroid
- steroid
- pyrazolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
يتعلق الاختراع الحالي بستيرويد 19-نور C3، 3- به استبدال ثنائي لـ C21-N- بيرازوليل بلوري له الصيغة (I)،
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 | |
| PCT/US2017/048267 WO2018039378A1 (en) | 2016-08-23 | 2017-08-23 | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JOP20190022A1 JOP20190022A1 (ar) | 2019-02-18 |
| JOP20190022B1 true JOP20190022B1 (ar) | 2023-03-28 |
Family
ID=59772778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0022A JOP20190022B1 (ar) | 2016-08-23 | 2017-08-23 | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11236121B2 (ar) |
| EP (2) | EP3504189A1 (ar) |
| JP (2) | JP2019524853A (ar) |
| KR (2) | KR20230079470A (ar) |
| CN (4) | CN115974955A (ar) |
| AR (3) | AR109393A1 (ar) |
| AU (3) | AU2017315682B2 (ar) |
| BR (1) | BR112019003637A2 (ar) |
| CA (1) | CA3034262A1 (ar) |
| CL (2) | CL2019000477A1 (ar) |
| CO (1) | CO2019002596A2 (ar) |
| EA (1) | EA201990565A1 (ar) |
| EC (1) | ECSP19020141A (ar) |
| IL (1) | IL302480A (ar) |
| JO (1) | JOP20190022B1 (ar) |
| MA (1) | MA46042A (ar) |
| MX (2) | MX2019002193A (ar) |
| PE (1) | PE20190915A1 (ar) |
| PH (1) | PH12019500375A1 (ar) |
| SG (1) | SG11201901445TA (ar) |
| TW (2) | TWI808945B (ar) |
| WO (1) | WO2018039378A1 (ar) |
| ZA (1) | ZA201901051B (ar) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108976272B (zh) | 2011-10-14 | 2021-05-25 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| KR20230172622A (ko) | 2013-04-17 | 2023-12-22 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| HUE051403T2 (hu) | 2013-04-17 | 2021-03-01 | Sage Therapeutics Inc | Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz |
| PT3021852T (pt) | 2013-07-19 | 2021-04-21 | Sage Therapeutics Inc | Esteroides neuroativos, composições e utilizações das mesmas |
| CA2921512A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| HUE051488T2 (hu) | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
| US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
| DK3250210T3 (da) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| RU2019103590A (ru) | 2016-07-11 | 2021-02-11 | Сейдж Терапьютикс, Инк. | С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения |
| JP2019524853A (ja) | 2016-08-23 | 2019-09-05 | セージ セラピューティクス， インコーポレイテッド | 結晶性１９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイド |
| WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
| AU2018334214A1 (en) * | 2017-09-14 | 2020-03-26 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| TW202039528A (zh) | 2018-12-05 | 2020-11-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| CN111454318A (zh) | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| US20220098230A1 (en) * | 2019-01-31 | 2022-03-31 | Shenzhen Rentai Pharmatech Ltd. | y-AMINOBUTYRIC ACID MODULATOR CRYSTAL FORM X, PREPARATION METHOD AND APPLICATION THEREOF |
| WO2020242772A1 (en) | 2019-05-28 | 2020-12-03 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| JP2022534424A (ja) | 2019-05-31 | 2022-07-29 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| KR20220066262A (ko) * | 2019-08-07 | 2022-05-24 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 스테로이드 유도체 조절제의 염 및 결정형 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| PE20231301A1 (es) | 2020-07-20 | 2023-08-24 | Sage Therapeutics Inc | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso de este |
| WO2022165017A1 (en) | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| JP2024510436A (ja) | 2021-03-17 | 2024-03-07 | セージ セラピューティクス， インコーポレイテッド | 大うつ病性障害の処置のための１９－ノルｃ３，３－２置換ｃ２１－ｎ－ピラゾリルステロイド |
| AU2022266680A1 (en) | 2021-04-29 | 2023-11-02 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| AU2022267304A1 (en) | 2021-04-29 | 2023-11-02 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| KR20240037975A (ko) | 2021-07-28 | 2024-03-22 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드의 결정질 형태 |
| WO2023158668A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| JP2003519698A (ja) * | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ，インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
| ES2356306T3 (es) | 2002-02-08 | 2011-04-06 | Ono Pharmaceutical Co., Ltd. | Compuestos y fármacos derivados de piperidina que contienen los compuestos como principio activo. |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| DK2925327T3 (da) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
| ES2680582T3 (es) | 2012-12-18 | 2018-09-10 | Washington University | Esteroides 19-alcoxi-17-sustituidos neuroactivos, profármacos de los mismos y métodos de tratamiento con los mismos |
| KR20230172622A (ko) | 2013-04-17 | 2023-12-22 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| HUE051488T2 (hu) | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| US20180250313A1 (en) | 2015-09-08 | 2018-09-06 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| US10780099B2 (en) | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| WO2017087864A1 (en) | 2015-11-20 | 2017-05-26 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| MA43815A (fr) | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | Stéroïdes neuroactifs, compositions, et leurs utilisations |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| RU2019103590A (ru) | 2016-07-11 | 2021-02-11 | Сейдж Терапьютикс, Инк. | С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| JP2019524853A (ja) | 2016-08-23 | 2019-09-05 | セージ セラピューティクス， インコーポレイテッド | 結晶性１９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイド |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| JP7196157B2 (ja) | 2017-08-31 | 2022-12-26 | 武田薬品工業株式会社 | Ｃｎｓ状態の治療 |
| WO2019051264A1 (en) | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| AU2018334214A1 (en) | 2017-09-14 | 2020-03-26 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| CN111565724A (zh) | 2017-11-10 | 2020-08-21 | 马瑞纳斯制药公司 | 加奈索酮用于治疗遗传性癫痫病 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| IL275562B1 (en) | 2017-12-22 | 2024-03-01 | Sage Therapeutics Inc | Preparations and methods for the treatment of central nervous system disorders |
| MA51316A (fr) | 2017-12-22 | 2020-10-28 | Sage Therapeutics Inc | Compositions et méthodes permettant de traiter les troubles du snc |
| JP2021510695A (ja) | 2018-01-12 | 2021-04-30 | セージ セラピューティクス， インコーポレイテッド | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア−プレグナン−２０−オン−３α−オール化合物 |
| CA3103421A1 (en) | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| WO2020077255A1 (en) | 2018-10-12 | 2020-04-16 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
| BR112021007401A2 (pt) | 2018-10-19 | 2021-08-03 | Sage Therapeutics, Inc. | esteroides neuroativos insaturados 9(11) e seus métodos de uso |
| TW202039528A (zh) | 2018-12-05 | 2020-11-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| CN113195512A (zh) | 2018-12-21 | 2021-07-30 | 萨奇治疗股份有限公司 | 3.α.-羟基-17.β.-酰胺神经活性类固醇及其组合物 |
| TW202110824A (zh) | 2019-05-24 | 2021-03-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| JP2022534424A (ja) | 2019-05-31 | 2022-07-29 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| EP4069250A1 (en) | 2019-12-05 | 2022-10-12 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| IL296371A (en) | 2020-03-18 | 2022-11-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| PE20231301A1 (es) | 2020-07-20 | 2023-08-24 | Sage Therapeutics Inc | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso de este |
-
2017
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/en active Application Filing
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es unknown
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 MX MX2019002193A patent/MX2019002193A/es unknown
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko not_active Application Discontinuation
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt active Search and Examination
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/en not_active Withdrawn
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 CA CA3034262A patent/CA3034262A1/en active Pending
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/en active Pending
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Application Discontinuation
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 TW TW112101437A patent/TW202342059A/zh unknown
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
-
2023
- 2023-08-24 US US18/455,324 patent/US20230399357A1/en active Pending
-
2024
- 2024-02-06 AU AU2024200732A patent/AU2024200732A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20190022B1 (ar) | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري | |
| PH12019501842A1 (en) | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
| PH12018501096A1 (en) | Modulators of chemokine receptors | |
| MX2020001278A (es) | Sintesis de compuestos de carbamoilpiridona policiclica. | |
| MX2020004504A (es) | Derivados de fenoximetilo. | |
| MX2017004672A (es) | Proceso para la preparacion de treprostinil. | |
| EA201790884A8 (ru) | 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr | |
| EA033445B1 (ru) | 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr | |
| MX2017002214A (es) | Proceso para la preparacion de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno. | |
| EP3795578A3 (en) | Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof | |
| MX2016015543A (es) | Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno. | |
| JOP20200030A1 (ar) | مركب خماسي الحلقة | |
| MX2017010901A (es) | Colorantes de acido trisazo. | |
| IN2014MU01192A (ar) | ||
| IN2014MU00195A (ar) | ||
| MX2019004024A (es) | Metodo para preparar acetofenonas sustituidas con ciclopropilo. | |
| MX2019003684A (es) | Formas cristalinas de un derivado de acido biliar. | |
| MX2023009432A (es) | Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio. | |
| IN2014MU00194A (ar) | ||
| IN2014MU01196A (ar) | ||
| WO2018198101A3 (en) | Processes for the preparation of crystalline form of eluxadoline | |
| WO2017098520A8 (en) | PROCESS FOR THE PREPARATION OF LABETALOL CHLORHYDRATE | |
| MX2018007638A (es) | Proceso mejorado para preparar crotonilaminopiridinas. | |
| MX2018011117A (es) | Forma cristalina. | |
| IN2014MU00858A (ar) |